Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
J Agric Food Chem ; 56(2): 502-6, 2008 Jan 23.
Article in English | MEDLINE | ID: mdl-18092749

ABSTRACT

Both primary and secondary alcohols degrade iprodione, 3-(3,5-dichlorophenyl)-N-(1-methylethyl)-2,4-dioxo-1-imidazolidine carboxamide. Steric hindrance has been found to have an inverse effect on the rate of its decomposition, and a fully substituted alcohol, such as tert-butanol, does not degrade iprodione due to extreme steric hindrance. The instability of iprodione in alcohol was found to be a function of the structure of the alcohol. The product, N-(3,5-dichlorophenyl)-3-(1-methylethyl)-2,4-dioxo-1-imidazolidine carboxamide, is obtained from all of the reacting alcohols. Confirmation of this structure came from the consideration of its NMR, mass spectral, and elemental analysis data.


Subject(s)
Alcohols/pharmacology , Aminoimidazole Carboxamide/analogs & derivatives , Fungicides, Industrial/chemistry , Hydantoins/chemistry , Aminoimidazole Carboxamide/chemistry , Drug Stability , Gas Chromatography-Mass Spectrometry , Magnetic Resonance Spectroscopy , Methanol/chemistry , Models, Molecular , Solutions , tert-Butyl Alcohol/pharmacology
2.
Bioconjug Chem ; 17(5): 1141-50, 2006.
Article in English | MEDLINE | ID: mdl-16984121

ABSTRACT

Liposomes have been a main focus of tumor-selective boron delivery strategies in boron neutron capture therapy (BNCT), a binary method for the treatment of cancer that is based on the nuclear reaction between boron atoms and low-energy thermal neutrons. Three novel carboranyl cholesterol derivatives were prepared as lipid bilayer components for the construction of nontargeted and receptor-targeted boronated liposomes for BNCT. A major structural feature of these novel boronated cholesterol mimics is the replacement of the B and the C ring of cholesterol with a carborane cluster. Computational analyses indicated that all three boronated compounds have structural features and physicochemical properties that are very similar to those of cholesterol. One of the synthesized boronated cholesterol mimics was stably incorporated into non-, folate receptor (FR)-, and vascular endothelial growth factor receptor-2 (VEGFR-2)-targeted liposomes. No major differences were found in appearance, size distribution, and lamellarity between conventional dipalmitoylphosphatidylcholine (DPPC)/cholesterol liposomes, nontargeted, and FR-targeted liposomal formulations of this carboranyl cholesterol derivative. FR-targeted boronated liposomes were taken up extensively in FR overexpressing KB cells in vitro, and the uptake was effectively blocked in the presence of free folate. In contrast, a boronated cholesterol mimic incorporated into nontargeted liposomes showed significantly lower cellular uptake. There was no apparent in vitro cytotoxicity in FR overexpressing KB cells and VEGFR-2 overexpressing 293/KDR cells when these were incubated with boronated FR- and (VEGFR-2)-targeted liposomes, respectively, although the former accumulated extensively in KB cells and the latter effectively interacted with VEGFR-2 by causing autophosphorylation and protecting 293/KDR cells from SLT (Shiga-like toxin)-VEGF cytotoxicity.


Subject(s)
Boron Compounds/metabolism , Boron Neutron Capture Therapy/methods , Cholesterol , Liposomes/metabolism , Boron Compounds/chemistry , Cell Line , Cholesterol/chemistry , Cholesterol/metabolism , Humans , Liposomes/chemistry , Models, Molecular , Molecular Structure , Neoplasms/therapy , Particle Size , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism
3.
Article in English | MEDLINE | ID: mdl-16901817

ABSTRACT

Concise synthetic methods for synthesizing 3-carboranyl thymidine analogues (3CTAs) modified with cyclic and acyclic alcohols have been developed. The synthesis of these potential boron neutron capture therapy (BNCT) agents and their preliminary biological evaluation is described.


Subject(s)
Boron Compounds/chemistry , Boron Neutron Capture Therapy , Neoplasms/radiotherapy , Thymidine/analogs & derivatives , Boron Compounds/chemical synthesis , Boron Compounds/metabolism , Humans , Phosphorylation , Thymidine Kinase/metabolism
4.
Bioorg Med Chem ; 14(20): 6886-99, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16831554

ABSTRACT

Five novel 3-carboranyl thymidine analogues (3CTAs) were designed and synthesized for boron neutron capture therapy (BNCT) of cancer. Phosphorylation of all five 3CTAs was catalyzed by recombinant human thymidine kinase (hTK1) using adenosine triphosphate (ATP) as the phosphate donor. The obtained phosphorylation rates ranged from 4% to 64.5% relative to that of thymidine. The compound with the most favorable hTK1 binding properties had a k(cat)/K(M) value of 57.4% relative to that of thymidine and an IC(50) of inhibition of thymidine phosphorylation by hTK1 of 92 microM. Among the five synthesized 3CTAs, this agent had also the overall most favorable physicochemical properties. Therefore, it may have the potential to replace N5-2OH, the current lead 3CTA, in preclinical studies. An in silico model for the binding of this compound to hTK1 was developed.


Subject(s)
Thymidine/analogs & derivatives , Thymidine/therapeutic use , Binding Sites , Boron Neutron Capture Therapy , Catalysis , Drug Design , Humans , Hydrophobic and Hydrophilic Interactions , Models, Molecular , Molecular Conformation , Neoplasms/radiotherapy , Phosphorylation , Protein Conformation , Protein Structure, Tertiary , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Stereoisomerism , Structure-Activity Relationship , Thymidine/chemistry , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/chemistry
5.
Bioorg Med Chem ; 14(16): 5699-710, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16675220

ABSTRACT

N(1)-Phenyl-3,5-dinitro-N(4),N(4)-di-n-propylsulfanilamide (1) and N(1)-phenyl-3,5-dinitro-N(4),N(4)-di-n-butylsulfanilamide (2) show potent in vitro antimitotic activity against kinetoplastid parasites but display poor in vivo activity. Seventeen new dinitroaniline sulfonamide and eleven new benzamide analogs of these leads are reported here. Nine of the sulfonamides display in vitro IC(50) values under 500 nM against African trypanosomes, and the most active antikinetoplastid compounds also inhibit the in vitro assembly of purified leishmanial tubulin with potencies similar to that of 2. While several of the potent compounds are rapidly degraded by rat liver S9 fractions in vitro, N(1)-(3-hydroxy)phenyl-3,5-dinitro-N(4),N(4)-di-n-butylsulfanilamide (21) displays an IC(50) value of 260 nM against African trypanosomes in vitro and is more stable than 2 in the in vitro metabolism assay.


Subject(s)
Antimitotic Agents/pharmacology , Antiprotozoal Agents/pharmacology , Benzamides/pharmacology , Kinetoplastida/drug effects , Leishmania donovani/drug effects , Sulfanilamides/pharmacology , Trypanosoma/drug effects , Animals , Antimitotic Agents/chemical synthesis , Antiprotozoal Agents/chemical synthesis , Benzamides/chemical synthesis , Inhibitory Concentration 50 , Liver/metabolism , Rats , Structure-Activity Relationship , Sulfanilamides/chemical synthesis , Tubulin/metabolism
6.
Anticancer Agents Med Chem ; 6(2): 127-44, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16529536

ABSTRACT

One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5'-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.


Subject(s)
Boranes/chemical synthesis , Boron Neutron Capture Therapy/methods , Nucleosides/chemical synthesis , Thymidine/analogs & derivatives , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/therapeutic use , Boranes/therapeutic use , Humans , Nucleosides/therapeutic use , Nucleotides/chemical synthesis , Nucleotides/therapeutic use , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/therapeutic use , Thymidine/chemical synthesis , Thymidine Kinase/metabolism
7.
Bioorg Med Chem ; 13(13): 4160-7, 2005 Jul 01.
Article in English | MEDLINE | ID: mdl-15876539

ABSTRACT

5'-Phosphorylation, catalyzed by human deoxycytidine kinase (dCK), is a crucial step in the metabolic activation of anticancer and antiviral nucleoside antimetabolites, such as cytarabine (AraC), gemcitabine, cladribine (CdA), and lamivudine. Recently, crystal structures of dCK (dCKc) with various pyrimidine nucleosides as substrates have been reported. However, there is no crystal structure of dCK with a bound purine nucleoside, although purines are good substrates for dCK. We have developed a model of dCK (dCKm) specific for purine nucleosides based on the crystal structure of purine nucleoside bound deoxyguanosine kinase (dGKc) as the template. dCKm is essential for computer aided molecular design (CAMD) of novel anticancer and antiviral drugs that are based on purine nucleosides since these did not bind to dCKc in our docking experiments. The active site of dCKm was larger than that of dCKc and the amino acid (aa) residues of dCKm and dCKc, in particular Y86, Q97, D133, R104, R128, and E197, were not in identical positions. Comparative docking simulations of deoxycytidine (dC), cytidine (Cyd), AraC, CdA, deoxyadenosine (dA), and deoxyguanosine (dG) with dCKm and dCKc were carried out using the FlexX docking program. Only dC (pyrimidine nucleoside) docked into the active site of dCKc but not the purine nucleosides dG and dA. As expected, the active site of dCKm appeared to be more adapted to bind purine nucleosides than the pyrimidine nucleosides. While water molecules were essential for docking experiments using dCKc, the absence of water molecules in dCKm did not affect the ability to correctly dock various purine nucleosides.


Subject(s)
Antineoplastic Agents/metabolism , Antiviral Agents/metabolism , Deoxycytidine Kinase/chemistry , Deoxycytidine Kinase/metabolism , Models, Molecular , Purine Nucleosides/metabolism , Amino Acid Sequence , Antineoplastic Agents/chemistry , Antiviral Agents/chemistry , Binding Sites , Computer Simulation , Humans , Molecular Sequence Data , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/chemistry , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Sequence Homology, Amino Acid , Substrate Specificity , Water/metabolism
8.
Bioorg Med Chem ; 13(5): 1681-9, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15698786

ABSTRACT

Thymidine kinase 1 (TK1) is a key target for antiviral and anticancer chemotherapy. Three-dimensional quantitative structure-activity relationship (3D-QSAR) using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques was applied to analyze the phosphorylation capacity of a series of 31 TK1 substrates. The optimal predictive CoMFA model with 26 molecules provided the following values: cross-validated r(2) (q(2))=0.651, non-cross-validated r(2)=0.980, standard error of estimate (s)=0.207, F=129.3. For the optimal CoMSIA model the following values were found: q(2)=0.619, r(2)=0.994, s=0.104, F=372.2. The CoMSIA model includes steric, electrostatic, and hydrogen bond donor fields. The predictive capacity of both models was successfully validated by calculating known phosphorylation rates of five TK1 substrates that were not included in the training set. Contour maps obtained from CoMFA and CoMSIA models correlated with the experimentally developed SAR.


Subject(s)
Thymidine Kinase/metabolism , Humans , Models, Molecular , Phosphorylation , Quantitative Structure-Activity Relationship , Substrate Specificity
9.
J Med Chem ; 48(4): 1188-98, 2005 Feb 24.
Article in English | MEDLINE | ID: mdl-15715485

ABSTRACT

Novel 3-carboranyl thymidine analogues (3CTAs) were synthesized as potential boron delivery agents for boron neutron capture therapy (BNCT). This library includes six zwitterionic NH(3)(+)-nido-m-carborane-substituted thymidine analogues (Thds) and the corresponding neutral NH(2)-closo-m-carborane-substituted counterparts. All compounds of this library were good substrates for recombinant human thymidine kinase 1 (TK1) with phosphorylation rates up to 89% relative to that of Thd. One compound out of this library, 3-[3-(7-NH(3)(+)-nido-m-carboran-1-yl)propan-1-yl]thymidine (19b), showed selective retention in TK1-expressing murine L929 wild-type tumors versus L929 TK1 (-) tumors in biodistribution studies. The biological evaluation of the zwitterionic NH(3)(+)-nido-m-carborane-substituted Thds indicated improved aqueous solubility and similar or even superior potential as BNCT agents compared with different classes of 3CTAs (Cancer Res. 2004, 64, 6280-6286 and 6287-6295). To complete previous structure-activity relationship (SAR) studies, 3-[(closo-o-carboranyl)methyl]thymidine (4) was also synthesized and evaluated.


Subject(s)
Boron Compounds/chemical synthesis , Thymidine/analogs & derivatives , Thymidine/chemical synthesis , Animals , Binding Sites , Biological Availability , Boron Compounds/chemistry , Boron Compounds/pharmacology , Boron Neutron Capture Therapy , Cell Line, Tumor , Humans , Ions , Mice , Mice, Nude , Phosphorylation , Solubility , Structure-Activity Relationship , Substrate Specificity , Thymidine/chemistry , Thymidine/pharmacology , Thymidine Kinase/chemistry , Thymidine Kinase/metabolism , Tissue Distribution , Xenograft Model Antitumor Assays
10.
Bioorg Med Chem ; 12(18): 4769-81, 2004 Sep 15.
Article in English | MEDLINE | ID: mdl-15336255

ABSTRACT

Eleven 3-carboranyl thymidine analogues (3CTAs) containing highly hydrophilic and flexible ethyleneoxide moieties were synthesized as potential agents for boron neutron capture therapy (BNCT) and their biochemical and physicochemical properties were evaluated. Based on specific structural features, this library of 3CTAs was divided into three subgroups. The first group contained 3CTAs with 1-4 ethyleneoxide units between the thymidine (Thd) scaffold and a carborane cluster. The second group of 3CTAs contained a pentylene spacer between Thd and the carborane and 2-4 ethyleneoxide units additionally attached to the carborane cluster. The third group contained three 3CTAs all with pentylene spacers and four ethylene units but with different carborane cages. The ethyleneoxide modified 3CTAs were good substrates of thymidine kinase 1 (TK1) and poor substrates of human mitochondrial thymidine kinase 2 (TK2) as determined in phosphoryl transfer assays. In the first group of 3CTAs, all the compounds were efficiently phosphorylated regardless of varying spacer lengths (37-42% of the activity of Thd). The second group of 3CTAs was less effectively phosphorylated (17-26% of the activity of Thd) probably due to a less favorable sterical orientation of Thd within the active site of TK1 and/or an increased lipophilicity compared with the first group. In the third group of structural isomers, no significant differences in phosphorylation rates were observed (17-25%). A structure-function hypothesis explaining these results is presented.


Subject(s)
Boron Compounds/chemical synthesis , Ethylene Oxide/chemical synthesis , Thymidine/analogs & derivatives , Thymidine/chemical synthesis , Boron Compounds/analysis , Drug Evaluation, Preclinical/methods , Ethylene Oxide/analysis , Humans , Thymidine/analysis
11.
Cancer Res ; 64(17): 6280-6, 2004 Sep 01.
Article in English | MEDLINE | ID: mdl-15342416

ABSTRACT

Thymidine analogs containing o-carboranylalkyl groups at the 3-position were screened as potential substrates for human thymidine kinase 1 (TK1), an enzyme that is selectively expressed in a variety of rapidly proliferating cells, including tumor cells. On the basis of previous studies, 12 of these were identified as potential delivery agents for boron neutron capture therapy, a therapeutic method used for the treatment of high-grade brain tumors. Compound 4 with a pentylene spacer between the o-carborane cage and the thymidine scaffold and compound 10, which has an additional dihydroxypropyl substituent at the o-carborane cage, were the best substrates for TK1 with kcat/Km values of 27% and 36% relative to that of thymidine, respectively. These compounds showed partial competitive inhibition for thymidine phosphorylation by TK1. Neither compound was a substrate of recombinant human thymidine phosphorylase nor were their respective 5'-monophosphates substrates of 5'-deoxynucleotidase 1, thereby indicating potential in vivo stability. The octanol/water partition coefficient for compound 10 was 2.09, suggesting that it has excellent physiochemical properties for crossing the blood brain barrier and penetrating brain tissue. The in vitro cytotoxic effect of the 12 analogs was moderate to low in mammalian cell cultures with IC50 values between 10 and 160 micromol/L. Compounds 4 and 10 were taken up selectively and retained by the murine fibroblast L929 cell line, in contrast to its TK1-deficient variant. These findings suggest that compound 10 is a promising candidate for selective delivery of boron-10 to malignant cells, and additional in vivo studies are planned to evaluate it for boron neutron capture therapy of brain tumors.


Subject(s)
Boron Neutron Capture Therapy/methods , Thymidine Kinase/metabolism , Thymidine/analogs & derivatives , 5'-Nucleotidase/antagonists & inhibitors , 5'-Nucleotidase/metabolism , Cell Line , Cytosol/enzymology , Humans , Kinetics , Nucleotidases/metabolism , Phosphorylation , Substrate Specificity , Thymidine/metabolism , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/deficiency
12.
Cancer Res ; 64(17): 6287-95, 2004 Sep 01.
Article in English | MEDLINE | ID: mdl-15342417

ABSTRACT

The purpose of the present study was to evaluate both in vitro and in vivo a series of boron-containing nucleosides that potentially could be used as delivery agents for neutron capture therapy. The rationale for their synthesis was based on the fact that proliferating neoplastic cells have increased requirements for nucleic acid precursors, and, therefore, they should preferentially localize in the tumor. A series of 3-carboranlyalkyl thymidine analogs has been synthesized and a subset, designated N4, N5, and N7, and the corresponding 3-dihydroxypropyl derivatives, designated N4-2OH, N5-2OH, and N7-2OH, have been selected for evaluation. Using these compounds as substrates for recombinant human thymidine kinase-1 and the mitochondrial isoenzyme thymidine kinase-2, the highest phosphorylation levels relative to thymidine were seen with N5 and the corresponding dihydroxypropyl analog N5-2OH. In contrast, N4, N4-OH, N7, and N7-OH had substantially lower phosphorylation levels. To compare compounds with high and low thymidine kinase-1 substrate activity, N5 and N7 and the corresponding dihydroxypropyl derivatives were selected for evaluation of their cellular toxicity, uptake and retention by the F98 rat glioma, human MRA melanoma, and murine L929 cell lines, all of which are thymidine kinase-1(+), and a mutant L929 cell line that is thymidine kinase-1(-). N5-2OH was the least toxic (IC50, 43-70 microm), and N7 and N7-2OH were the most toxic (IC50, 18-49 microm). The highest boron uptake was seen with N7-2OH by the MRA 27 melanoma and L929 wild-type (wt) cell lines. The highest retention was seen with L929 (wt) cells, and this ranged from 29% for N5-2OH to 46% for N7. Based on the in vitro toxicity and uptake data, N5-2OH was selected for in vivo biodistribution studies either in rats bearing intracerebral implants of the F98 glioma or in mice bearing either s.c. or intracerebral implants of L929 (wt) tumors. At 2.5 hours after convection-enhanced delivery, the boron values for the F98 glioma and normal brain were 16.2 +/- 2.3 and 2.2 microg/g, respectively, and the tumor to brain ratio was 8.5. Boron values at 4 hours after convection-enhanced delivery of N5-2OH to mice bearing intracerebral implants of L929 (wt) or L929 thymidine kinase-1(-) tumors were 39.8 +/- 10.8 and 12.4 +/- 1.6 microg/g, respectively, and the corresponding normal brain values were 4.4 and 1.6 microg/g, thereby indicating that there was selective retention by the thymidine kinase-1(+) tumors. Based on these favorable in vitro and in vivo data, neutron capture therapy studies will be initiated using N5-2OH in combination with two non-cell cycle dependent boron delivery agents, boronophenylalanine and sodium borocaptate.


Subject(s)
Boron Compounds/pharmacology , Boron Neutron Capture Therapy/methods , Brain Neoplasms/radiotherapy , Phenylalanine/analogs & derivatives , Thymidine/analogs & derivatives , Animals , Boron Compounds/pharmacokinetics , Brain Neoplasms/metabolism , Cell Division/physiology , Glioma/metabolism , Glioma/radiotherapy , Humans , Male , Mice , Mice, Inbred C3H , Mice, Nude , Middle Aged , Phenylalanine/pharmacokinetics , Phosphorylation , Rats , Rats, Inbred F344 , Spectrometry, Mass, Secondary Ion , Subcellular Fractions/metabolism , Thymidine/pharmacokinetics , Thymidine/pharmacology , Thymidine Kinase/metabolism
13.
Appl Radiat Isot ; 61(5): 1125-30, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15308203

ABSTRACT

Several thymidine analogues substituted with closo- and nido-carborane at the N-3 position were synthesized. The nido-carboranyl thymidine analogues were designed to be effective substrates for human thymidine kinase 1 in combination with an increased water solubility sufficient for clinical application in boron neutron capture therapy. This was done because N-3 substituted closo-carboranyl thymidine analogues previously synthesized in our laboratories were good TK1 substrates but were poorly water-soluble. Newly synthesized zwitterionic amino nido- and the corresponding neutral closo-m-carboranyl thymidine analogues exhibited excellent TK1 phosphorylation rates up to 75% relative to thymidine, indicating that these compounds were good substrates for thymidine kinase 1. Thin layer chromatographic studies were indicative of increased hydrophilicity of the synthesized nido-carboranyl thymidine analogues compared with their closo-carboranyl counterparts and previously reported closo-carboranyl thymidine analogues.


Subject(s)
Thymidine/analogs & derivatives , Boron Neutron Capture Therapy , Humans , In Vitro Techniques , Molecular Structure , Phosphorylation , Recombinant Proteins/metabolism , Solubility , Substrate Specificity , Thymidine/chemical synthesis , Thymidine/chemistry , Thymidine/metabolism , Thymidine Kinase/metabolism
14.
Bioorg Med Chem Lett ; 13(19): 3213-6, 2003 Oct 06.
Article in English | MEDLINE | ID: mdl-12951095

ABSTRACT

Computer-aided molecular design (CAMD) of carborane containing compounds is of growing interest for scientists involved in boron neutron capture therapy (BNCT) and other pharmaceutical applications. However, the complex organo-metallic structures of carboranes pose difficulties in modeling and docking of these structures. This is the first report of a new strategy for modeling and docking of carborane containing molecules with the readily available software packages HyperChem, SYBYL and FlexX. It is intended as a guide for boron chemists interested in using CAMD of carborane containing agents for medical applications such as BNCT.


Subject(s)
Boranes/chemistry , Computer-Aided Design , Boranes/metabolism , Molecular Structure
15.
J Med Chem ; 45(18): 4018-28, 2002 Aug 29.
Article in English | MEDLINE | ID: mdl-12190323

ABSTRACT

A small library consisting of two series of thymidine derivatives containing o-carboranylalkyl groups at the N-3 position was prepared. In both series, alkyl spacers of 2-7 methylene units were placed between the o-carborane cage and the thymidine scaffold. In one series, an additional dihydroxypropyl substituent was introduced at the second carbon atom of the carborane cage. In the series of N-3-substituted carboranyl thymidines without additional dihydroxypropyl substituent, three steps were required to obtain the target compounds in overall yields as high as 75%, while in the series of N-3-substituted carboranyl thymidines with additional dihydroxypropyl substituent, 9-10 steps were necessary with significantly lower overall yield. All target compounds were good substrates of human cytosolic thymidine kinase 1 while they were, if at all, poor substrates of the mitochondrial thymidine kinase 2. There was only a minor difference in phosphorylation rates between N-3-substituted carboranyl thymidines with additional dihydroxypropyl substituents with thymidine kinase 1 (range: 13-49% relative to thymidine) and their counterparts lacking this group (range: 11-57% relative to thymidine). Tether lengths of two and five methylene groups in both series gave the highest enzyme activities in the present study. A hypothesis for this result is presented.


Subject(s)
Boron Compounds/chemical synthesis , Thymidine Kinase/chemistry , Thymidine/analogs & derivatives , Thymidine/chemical synthesis , Boron Compounds/chemistry , Combinatorial Chemistry Techniques , Humans , Structure-Activity Relationship , Substrate Specificity , Thymidine/chemistry
16.
Bioorg Med Chem Lett ; 12(16): 2209-12, 2002 Aug 19.
Article in English | MEDLINE | ID: mdl-12127539

ABSTRACT

Boron neutron capture therapy (BNCT) is a chemoradio-therapeutic method for the treatment of cancer. It depends on the selective targeting of tumor cells by boron-containing compounds. One category of BNCT agents with potential to selectively target tumor cells may be thymidine derivatives substituted at the 3'-position with appropriate boron moieties. Thus, several thymidine analogues were synthesized with a carborane cluster bound to the 3'-position either through an ether or a carbon linkage. The latter are the first reported carborane-containing nucleosides in which the carboranyl entity is directly linked to the carbohydrate portion of the nucleoside by a carbon-carbon bond. Low but significant phosphorylation rates in the range of 0.18% that of thymidine were observed for the carbon-linked 3'-carboranyl thymidine analogues in phosphoryl transfer assays using recombinant preparations of thymidine kinases 1 (TK1) and thymidine kinases 2 (TK2). Some of the ether-linked 3'-carboranyl thymidine analogues appeared to be slightly unstable under acidic as well as phosphoryl transfer assay conditions and were, if at all, poor substrates for TK1.


Subject(s)
Boron Compounds/chemistry , Boron Neutron Capture Therapy , Thymidine/analogs & derivatives , Thymidine/pharmacology , Drug Design , Molecular Structure , Phosphorylation , Thymidine/chemical synthesis , Thymidine/chemistry , Thymidine Kinase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...